SecBot SecBot
SECBOTREPLAY Home › Report › OTLK

OTLK · Outlook Therapeutics granted stock options to its CEO (100,000 options)…

Outlook Therapeutics, Inc. · 8-K filed Jul 23, 2026 at 19:54 ET

At the news

NEUTRALIMPACT 3/10

8-K filed Jul 23, 2026 at 19:54 ET

Outlook Therapeutics granted stock options to its CEO (100,000 options) and CFO (210,078 options) at $1.4304/share, vesting in July 2027, and approved cash bonuses of $420,000 (CEO) and $200,000 (CFO) contingent on FDA approval of ONS-5010 by July 31, 2026. This is a routine compensatory arrangement tied to the BLA process, not a departure or material change in leadership, and carries no immediate financial impact for shareholders beyond the potential cash payout if the FDA milestone is met within days.

  • CEO Robert C. Jahr received 100,000 stock options at $1.4304/share, vesting July 21, 2027.
  • CFO Lawrence A. Kenyon received 210,078 stock options at $1.4304/share, vesting July 21, 2027.
  • CEO awarded a cash bonus opportunity of $420,000, payable only if FDA approves ONS-5010 by July 31, 2026.
  • CFO awarded a cash bonus opportunity of $200,000, payable only if FDA approves ONS-5010 by July 31, 2026.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access